Monitor the company's appeal of the Nasdaq delisting notice, as the outcome will determine continued listing. The analytical development update is incremental and does not change the near-term risk of delisting or the lack of revenue.
Price Chart
Executive Summary
Propanc Biopharma provided a press release detailing analytical development progress for its lead candidate PPC-001, including immunogenicity assay feasibility, PK method optimization, and stability testing. However, the company faces an imminent Nasdaq delisting on November 2, 2026, due to non-compliance with the minimum bid price rule, and has not yet demonstrated a successful appeal. The press release contains no financial data, no regulatory approval, and no clinical results, making it a routine operational update with no material impact on the company's fundamental outlook.
Key Facts
- Propanc announced analytical development activities for PPC-001, including immunogenicity assay feasibility, PK method optimization, and stability testing.
- Stability studies showed PPC-001 components remained detectable without significant degradation over tested periods, with recovery exceeding 85% after 60 minutes at room temperature.
- The company received a delisting notice from Nasdaq on October 23, 2026, with delisting scheduled for November 2, 2026, unless an appeal is filed by October 30, 2026.
- The press release contains no financial results, no regulatory decisions, no clinical trial data, and no guidance.
- Market cap is approximately $2 million, and the stock has a normal daily move of 6.7%.
Financial Impact
No financial figures disclosed; the press release is a routine operational update.
Risk Factors
- Imminent Nasdaq delisting on November 2, 2026, if appeal is not successful or deficiency not cured.
- No revenue, no approved products, and early-stage development with significant capital requirements.
- Forward-looking statements about clinical development are subject to substantial uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3392217 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | Press Release | $2.10 | awaiting T+5 | awaiting T+5 | $1.84 (−12.38%) |
Oct 29, 2026 3d ago | 8-K | $2.14 | awaiting T+5 | awaiting T+5 | $1.84 (+14.02%) |
Oct 28, 2026 4d ago | Press Release | $2.11 | awaiting T+5 | awaiting T+5 | $1.84 (−12.80%) |
Oct 22, 2026 10d ago | Press Release | $0.2800 $0.1840 | ▼ −34.29% | ▼ −33.73% | $1.84 (+557.14%) |
Oct 5, 2026 27d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | $1.84 (−274.52%) |
Sep 29, 2026 4w ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | $1.84 (+259.16%) |
Aug 18, 2026 10w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | $1.84 (+58.62%) |
Jul 14, 2026 15w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | $1.84 (+12.88%) |
May 19, 2026 23w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | $1.84 (−8.23%) |
May 15, 2026 24w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | $1.84 (+8.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers